nach oben

Der Nervenarzt

Erschienen in:

01.06.2009 | Übersichten

Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien

verfasst von: M. Stangel, H.-P. Hartung, R. Gold, Prof. Dr. B.C. Kieseier

Erschienen in: Der Nervenarzt | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Langzeittherapie immunvermittelter Polyneuropathien ist nach wie vor eine Herausforderung. Bei der akut verlaufenden Polyneuritis, dem Guillain-Barré-Syndrom, gelten hochdosierte polyvalente intravenöse Immunglobuline (IVIG) als etablierte Therapieoption. Eine unlängst publizierte randomisierte, placebokontrollierte Studie bei Patienten mit chronisch entzündlicher demyelinisierender Polyradikuloneuropathie (CIDP) zeigte, dass IVIG auch bei dieser Krankheitsentität sowohl kurz- als auch langfristig klinisch wirksam sind und dabei eine gute Verträglichkeit aufweisen.

In dieser Übersichtsarbeit sollen die Daten dieser so genannten ICE-Studie („Intravenous immune globulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy study“) dargestellt sowie der Stellenwert von IVIG zur Behandlung immunvermittelter Polyneuropathien diskutiert werden.

Nur mit Berechtigung zugänglich

Kieseier BC, Hartung HP, Wiendl H (2006) Immune circuitry in the peripheral nervous system. Curr Opin Neurol 19:437–445PubMedCrossRef

Meyer zu Horste G, Hu W, Hartung HP et al (2008) The immunocompetence of schwann cells. Muscle Nerve 37:3–13CrossRef

Kieseier BC, Wiendl H, Hartung HP (2006) The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 19:433–436PubMedCrossRef

Gold R, Kieseier BC (2006) Therapy of immune neuropathies with intravenous immunoglobulins. J Neurol 253:V59–V63PubMedCrossRef

Meyer zu Horste G, Hartung HP, Kieseier BC (2007) From bench to bedside–experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 3:198–211CrossRef

Mäurer M, Gold R (2002) Animal models of immune-mediated neuropathies. Curr Opin Neurol 15:617–622PubMedCrossRef

Bosboom WM, Van den Berg LH, Mollee I et al (2001) Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology 56:74–81PubMed

Illes Z, Kondo T, Newcombe J et al (2000) Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 164:4375–4381PubMed

Schmidt B, Toyka KV, Kiefer R et al (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19:474–487PubMedCrossRef

10.

Winer J, Hughes S, Cooper J et al (2002) gammadelta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 249:616–621PubMedCrossRef

11.

Illes Z, Shimamura M, Newcombe J et al (2004) Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 16:223–230PubMedCrossRef

12.

Koga M, Yuki N, Tsukada Y et al (2003) CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barre and Fisher syndromes. J Neuroimmunol 141:112–117PubMedCrossRef

13.

Gold R, Archelos JJ, Hartung H-P (1999) Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 9:343–360PubMed

14.

Griffin JW, George R, Ho T (1993) Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 52:553–560PubMedCrossRef

15.

Kiefer R, Kieseier BC, Stoll G et al (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64:109–127PubMedCrossRef

16.

Kieseier BC, Kiefer R, Gold R et al (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131–156PubMedCrossRef

17.

Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591–2625PubMedCrossRef

18.

Yuki N, Susuki K, Koga M et al (2004) Carbohydrate mimicry between human ganglioside GM1 and campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 101:11404–11409PubMedCrossRef

19.

Yuki N, Yamada M, Koga M et al (2001) Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganliosides. Ann Neurol 49:712–720PubMedCrossRef

20.

Hartung H-P, Willison H, Kieseier BC (2002) Acute immunoinflammatory neuropathy: Update on Guillain-Barré Syndrome. Curr Opin Neurol 15:571–577PubMedCrossRef

21.

Halstead SK, Zitman FM, Humphreys PD et al (2008) Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131:1197–1208PubMedCrossRef

22.

Jacobs BC, O’Hanlon GM, Bullens RW et al (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126:2220–2234PubMedCrossRef

23.

Buchwald B, Weishaupt A, Toyka KV et al (1998) Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 10:281–290PubMedCrossRef

24.

Dilley A, Gregson NA, Hadden RD et al (2003) Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barre syndrome. J Neuroimmunol 139:133–140PubMedCrossRef

25.

Krampfl K, Mohammadi B, Buchwald B et al (2003) IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels. Muscle Nerve 27:435–441PubMedCrossRef

26.

Katz U, Achiron A, Sherer Y et al (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257–259PubMedCrossRef

27.

Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721–730PubMed

28.

Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology–therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44PubMedCrossRef

29.

Siberil S, SriRamulu E, Vir-Singh N et al (2007) Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 37:103–107PubMedCrossRef

30.

Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670–673PubMedCrossRef

31.

Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573–581PubMedCrossRef

32.

Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513–533 ReviewPubMedCrossRef

33.

Bril V, Ilse WK, Pearce R et al (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46:100–103PubMed

34.

Plasma, Exchange/Sandoglobulin, Guillain-Barré et al (1997) Randomised trial of plasma exchange, intravenous immuoglobulin and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230CrossRef

35.

van der Meché FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123–1129CrossRef

36.

Diener HC, Haupt WF, Kloss TM et al (2001) A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange and immune adsorption in Guillain-Barre syndrome. Eur Neurol 46:107–109PubMedCrossRef

37.

Hosokawa T, Hamaguchi K, Tomioka R et al (1998) Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Ther Apher Dial 2:288–291CrossRef

38.

Hughes RA, Swan AV, Raphael JC et al (2007) Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130:2245–2257PubMedCrossRef

39.

Imbach P, Barandun S, d’Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231PubMedCrossRef

40.

Raphael JC, Chevret S, Harboun M et al (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238PubMedCrossRef

41.

Korinthenberg R, Schessl J, Kirschner J et al (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 116:8–14PubMedCrossRef

42.

Visser LH, Van der Meche FG, Van Doorn PA et al (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barre Study Group. Brain 118:841–847PubMedCrossRef

43.

Yuki N, Ang CW, Koga M et al (2000) Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 47:314–321PubMedCrossRef

44.

Jacobs BC, van Doorn PA, Schmitz PI et al (1996) Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 40:181–187PubMedCrossRef

45.

Hadden RD, Karch H, Hartung HP et al (2001) Preceding infections, immune factors and outcome in Guillain-Barre syndrome. Neurology 56:758–765PubMed

46.

van Koningsveld R, Schmitz PI, Meche FG et al (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192–196CrossRef

47.

Stangel M, Gold R, Einsatz von i.v (2004) Immunglobulinen in der Neurologie. Nervenarzt 75:801–815PubMedCrossRef

48.

Linker RA, Gold R (2008) Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 21:358–365PubMedCrossRef

49.

Köller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356PubMedCrossRef

50.

Doorn P van, Brand A, Strengers P et al (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209–212PubMed

51.

Hahn AF, Bolton CF, Zochodne D et al (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119:1067–1077PubMedCrossRef

52.

Cornblath DR, Chaudry V, Griffin JW (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 30:104–106PubMedCrossRef

53.

Schaik IN van, Winer JB, Haan R de et al (2002) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 1:491–498PubMedCrossRef

54.

Hahn AF, Bolton CF, Pillay N et al (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119(Pt 4):1055–1066PubMedCrossRef

55.

Mendell JR, J BR, Freimer ML et al (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demeylinating polyradiculoneuropathy. Neurology 56:445–449PubMed

56.

Hughes R, Bensa S, Willison H et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculopathy. Ann Neurol 50:195–201PubMedCrossRef

57.

European Federation of Neurological Societies, Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy (2005) Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 10:220–228CrossRef

58.

Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144PubMedCrossRef

59.

Sander HW, Latov N (2003) Research criteria for defining patients with CIDP. Neurology 60:S8–S15PubMed

60.

Vermeulen M (2008) Intravenous immunoglobulin: a first-line treatment in CIDP? Lancet Neurol 7:115–116PubMedCrossRef

61.

Vermeulen M, Doorn PA van, Brand A et al (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39PubMedCrossRef

62.

Thompson N, Choudhary P, Hughes RA, Quinlivan RM (1996) A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 243:280–285PubMedCrossRef

63.

Asseldonk JT Van, Franssen H, Berg-Vos RM Van den et al (2005) Multifocal motor neuropathy. Lancet Neurol 4:309–319PubMedCrossRef

64.

Azulay JP, Blin O, Pouget J et al (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44:429–432PubMed

65.

Federico P, Zochodne DW, Hahn AF et al (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256–1262PubMed

66.

Leger JM, Chassande B, Musset L et al (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145–153PubMedCrossRef

67.

Berg LH Van den, Kerkhoff H, Oey PL et al (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252PubMedCrossRef

68.

Berg-Vos RM Van den, Franssen H, Wokke JH et al (2000) Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48:919–926PubMedCrossRef

69.

Nobile-Orazio E, Cappellari A, Meucci N et al (2002) Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 72:761–766PubMedCrossRef

70.

Ellis CM, Leary S, Payan J et al (1999) Use of human intravenous immunoglobulin in lower motor neuron syndromes. J Neurol Neurosurg Psychiatry 67:15–19PubMedCrossRef

71.

Joint Task Force of the EFNS and the PNS (2006) European federation of neurological societies / peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the european federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 11:1–8CrossRef

72.

Leger JM, Viala K, Cancalon F et al (2008) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 79:93–96PubMedCrossRef

73.

Terenghi F, Cappellari A, Bersano A et al (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62:666–668PubMed

74.

Lozeron P, Adams D (2007) Monoclonal gammopathy and neuropathy. Curr Opin Neurol 20:536–541PubMed

75.

Comi G, Roveri L, Swan A et al (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370–1377PubMedCrossRef

76.

Gorson KC, Ropper AH, Weinberg DH et al (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772PubMedCrossRef

77.

Joint Task Force of the EFNS and the PNS (2006) European Federation of Neurological Societies / Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 11:9–19CrossRef

78.

Kieseier BC, Meyer zu Hörste G, Lehmann HC et al (2008) Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol (in press)

79.

Koller H, Schroeter M, Feischen H et al (2006) Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253:1505–1506PubMedCrossRef

80.

Lee DH, Linker RA, Paulus W et al (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37:406–409PubMedCrossRef

Titel: Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien
verfasst von: M. Stangel
H.-P. Hartung
R. Gold
Prof. Dr. B.C. Kieseier
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 6/2009
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-008-2631-y

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Tiefe Hirnstimulation bei Dystonie

Nachruf auf Prof. Dr. med. Hans Schliack

Tetraparese bei hypertensiver Entgleisung

Bericht vom NeuroUpdate der Med-Update-Reihe in Wiesbaden (13./14.02.09)

Tiefe Hirnstimulation bei Multiple-Sklerose-Tremor

Multiple Sklerose und Sport

Neu in den Fachgebieten Neurologie und Psychiatrie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer